Get the Stockscreener App
39.61
5.18%
1.95
Anaptysbio Inc stock is traded at $39.61, with a volume of 1.53M.
It is up +5.18% in the last 24 hours and up +16.12% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$37.66
Open:
$33.375
24h Volume:
1.53M
Relative Volume:
2.60
Market Cap:
$1.10B
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-6.5148
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
+17.12%
1M Performance:
+16.12%
6M Performance:
+90.39%
1Y Performance:
+87.10%
1-Day Range:
$33.10
$40.13
1-Week Range:
$33.01
$40.13
52-Week Range:
$12.21
$40.96
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
39.61 | 1.04B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
Share Buyback Program Declared by AnaptysBio (NASDAQ:ANAB) Board of Directors - MarketBeat
AnaptysBio Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Double Or Triple Capital - earlytimes.in
AnaptysBio (NASDAQ:ANAB) Shares Gap DownTime to Sell? - MarketBeat
AnaptysBio sets $100M stock repurchase plan - MSN
AnaptysBio expands stock repurchase plan by $100 million - Investing.com Nigeria
Tesaro and AnaptysBio Enter Legal Battle Over Suspected Breach in Contract - PharmExec.com
European Equities Close Mixed in Friday Trading; Eurozone Composite PMI Continues to Expand - MarketScreener
GSK, Anaptysbio sue each other over Jemperli revenue - BioPharma Dive
AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters
Legal Battle Puts AnaptysBio's Jemperli Royalties At Risk - Finimize
AnaptysBio files lawsuit against Tesaro and GSK over collaboration agreement By Investing.com - Investing.com South Africa
AnaptysBio (ANAB) Faces Legal Battle with GSK's Subsidiary Over Cancer Drug Agreement - GuruFocus
ANAB Stock Falls After Company Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal - Stocktwits
AnaptysBio Expands Stock Repurchase Plan by $100M - TipRanks
AnaptysBio files lawsuit against Tesaro and GSK over collaboration agreement - Investing.com India
GSK and AnaptysBio Lock Horns Over Jemperli Deal - Citeline News & Insights
AnaptysBio (ANAB) Shares Plunge Amid Legal Battle with GSK - GuruFocus
GSK subsidiary TESARO files lawsuit against AnaptysBio over Jemperli license - Investing.com
[8-K] ANAPTYSBIO, INC Reports Material Event | ANAB SEC FilingForm 8-K - Stock Titan
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga
AnaptysBio stock falls after filing lawsuit against GSK unit - Investing.com
AnaptysBio drops after litigation with GSK unit (ANAB:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
GSK, AnaptysBio Sue Each Other Over Cancer Drug License - The Wall Street Journal
GSK unit and AnaptysBio trade lawsuits over Jemperli - pharmaphorum
AnaptysBio (ANAB) Expands Stock Buyback Program to $100 Million - GuruFocus
AnaptysBio Launches $100 Million Share Buyback Program - MarketScreener
AnaptysBio Files Complaint Alleging GSK's Tesaro Breached Jemperli Collaboration Deal - MarketScreener
AnaptysBio Sues Tesaro, GSK Over Alleged Breaches of Jemperli License Deal - MarketScreener
Will AnaptysBio Inc. (AN6) stock beat international competition2025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
GSK Faces Legal Challenge Over Alleged Interference with Anaptys - GuruFocus
AnaptysBio Approves Amended $100 Mln Stock Repurchase Plan - Nasdaq
GSK files suit against AnaptysBio over licensing rights - Vox Markets
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary - The Manila Times
AnaptysBio (Nasdaq: ANAB) Announces $100M Stock Buyback Plan Through 2026 - Stock Titan
AnaptysBio files lawsuit against Tesaro over collaboration breach - StreetInsider
GSK’s TESARO Initiates Litigation Against AnaptysBio - AskTraders.com
GSK's Tesaro Sues AnaptysBio Over Jemperli License Breach - MarketScreener
TESARO Pursues Litigation Against AnaptysBio For Alleged Material Breach Of Jemperli Agreement - Nasdaq
GSK arm Tesaro initiates litigation against AnaptysBio - Medical Dialogues
GSK Starts Litigation Against AnaptysBio Inc - MarketWatch
GSK subsidiary TESARO sues AnaptysBio over cancer drug licensing dispute By Investing.com - Investing.com Australia
GSK unit sues AnaptysBio in row over Jemperli rights - Proactive financial news
TESARO Initiates Legal Action Against AnaptysBio Over Jemperli License - TipRanks
GSK subsidiary TESARO sues AnaptysBio over cancer drug licensing dispute - Investing.com
REGGSK PLCInitiation of litigation against AnaptysBio Inc - TradingView
GSK subsidiary Tesaro sues AnaptysBio over Jemperli license breach - MarketScreener
GSK (GSK) Pursues Legal Action Against AnaptysBio Over License D - GuruFocus
TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc. - GSK
AnaptysBio, Inc. authorizes a Buyback Plan. - MarketScreener
Savant Capital LLC Takes Position in AnaptysBio, Inc. $ANAB - MarketBeat
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Sep 30 '25 |
Sale |
29.00 |
8,240 |
238,960 |
9,088 |
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):